Company Overview

PRIME exits® and American Healthcare Capital are pleased to be the exclusive representative of a pioneering molecular diagnostics company is redefining women’s and prenatal health through its next generation, multiomic liquid biopsy platform. Leveraging methylation sequencing, proprietary AI analytics, and integrated clinical partnerships, the company enables earlier, non-invasive detection of complex diseases that were previously identifiable only through surgery, advanced imaging, or after symptom onset.

The Problem

Across women’s and prenatal health, delayed or inaccurate diagnosis remains one of the most persistent and costly challenges in modern medicine.

In women’s health, conditions such as endometriosis and adenomyosis affect nearly 190 million women globally, yet the average time to diagnosis can exceed 7 to 10 years. This delay not only prolongs patient suffering but leads to billions in unnecessary surgical costs and fertility complications.

In prenatal care, clinicians face an equally pressing challenge. While existing non-invasive prenatal tests (NIPTs) focus solely on chromosomal abnormalities, they fail to detect the broader maternal and fetal risks—such as preeclampsia, preterm birth, and gestational diabetes, that drive poor outcomes and over $2 billion in annual healthcare costs in the U.S.

Both sectors are hampered by the same structural barrier: limited access to scalable, affordable, and clinically actionable molecular testing that can detect multiple conditions early, before symptoms or complications appear.

The Solution

A breakthrough molecular diagnostics company has developed a multiomic liquid biopsy platform that solves this problem through early, non-invasive detection using a single blood sample.

The company’s two flagship assays address complementary unmet needs:

• Assay One: Detects women’s pain-related and reproductive disorders, replacing surgical diagnosis with a methylation-based, blood-only test.

• Assay Two: Expands prenatal screening beyond fetal genetics to include maternal health indicators such as preeclampsia and gestational diabetes.

Powered by proprietary methylation sequencing technology and AI-driven analytics, these Smart Learning Assays deliver multi-condition testing with 2.5x higher genomic coverage at less than half the cost of conventional sequencing, creating a high-margin, scalable solution positioned for widespread adoption.

Performance & Market Readiness

• CLIA-certified laboratory with over 30,000 completed tests across multiple indications.

• Revenue on pace to exceed $2 million in 2025, with strong visibility toward $3.5 million in 2026.

• Approximately $6 million raised from strategic and institutional investors to date, supporting assay validation, IP protection, and biobank development.

• Operating within two rapidly expanding markets exceeding $7.5 billion in combined TAM by 2030.

Transaction Rationale & Valuation Guidance

The shareholders are seeking a majority or full acquisition to accelerate growth through broader commercialization, reimbursement expansion, and international market entry. Key management will remain post-transaction to support scientific continuity and integration.

Asking Price & Valuation Guidance

The company invites market-consistent offers reflective of comparable transactions in women’s health and prenatal diagnostics. Final valuation will be determined collaboratively through discussions with qualified acquirers, based on growth trajectory, proprietary IP, and strategic fit. This opportunity represents a rare, de-risked entry into precision women’s and prenatal health, where early revenue, market-readiness, and proprietary IP converge to solve one of the most expensive and overlooked problems in modern medicine.